Frequency of Th17 CD4+ T cells in early rheumatoid arthritis: A marker of anti-CCP seropositivity

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Arroyo Villa, Irene ^a   Bautista Caro, María Belén ^a   Balsa, Alejandro ^a   Aguado Acín, Pilar ^a   Nuño, Laura ^a   Bonilla Hernán, María Gema ^a   Puig Kröger, Amaya ^b   Martín Mola, Emilio ^a   Miranda Carús, María Eugenia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR6; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; PHENOTYPE; POLYCLONAL ACTIVATION; RHEUMATOID ARTHRITIS; SUPERNATANT; SYNOVIAL FLUID; TH1 CELL; TH17 CELL;

ADULT; AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CYTOKINES; FEMALE; HUMANS; MALE; MIDDLE AGED; SYNOVIAL FLUID; TH1 CELLS; TH17 CELLS;

EID: 84864541677     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042189     Document Type: Article

References (40)

1. Sarkar S, Fox DA, (2010) Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 36: 345-366.
2. Nakae S, Nambu A, Sudo K, Iwakura Y, (2003) Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171: 6173-6177.
3. Bush KA, Farmer KM, Walker JS, Kirkham BW, (2002) Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 46: 802-805.
4. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, et al. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 50: 650-659.
5. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, et al. (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 170: 2655-2662.
6. Plater-Zyberk C, Joosten LA, Helsen MM, Koenders MI, Baeuerle PA, et al. (2009) Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann Rheum Dis 68: 721-728.
7. Buckland J, (2011) Experimental arthritis: Therapeutic promise of dual blockade of IL-17 and TNF in inflammatory arthritis. Nat Rev Rheumatol 7: 311.
8. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, et al. (1999) Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 42: 963-970.
9. Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, et al. (2000) High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164: 2832-2838.
10. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, et al. (2009) In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses. Proc Natl Acad Sci USA 106: 6232-6237.
11. Stamp LK, Easson A, Petterson L, Highton J, Hessian PA, (2009) Monocyte Derived Interleukin (IL)-23 Is an Important Determinant of Synovial IL-17A Expression in Rheumatoid Arthritis. J Rheumatol 36: 2403-2408.
12. Pène J, Chevalier S, Preisser L, Vénéreau E, Guilleux MH, et al. (2008) Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 180: 7423-7430.
13. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, et al. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62: 929-939.
14. Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, et al. (2011) Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 18: 2602-2612.
15. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, et al. (2009) Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 60: 2294-2303.
16. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, et al. (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184: 3336-3340.
17. Suurmond J, Dorjée AL, Boon MR, Knol EF, Huizinga TW, et al. (2011) Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and-negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 13: R150.
18. Aerts NE, De Knop KJ, Leysen J, Ebo DG, Bridts CH, et al. (2010) Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression. Rheumatology (Oxford) 49: 2264-2272.
19. Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM (2008) Th-17 cells in rheumatoid arthritis. Arthritis Res Ther 10: R93.
20. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, et al. (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 62: 2876-2885.
21. Rossol M, Kraus S, Pierer M, Baerwald C, Wagner U, (2012) The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes Th17 expansion. Arthritis Rheum 64: 671-677.
22. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushi JI, et al. (2008) Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Ann Rheum Dis 67: 1299-12304.
23. Nistala K, Moncrieffe H, Newton KR, Varsani H, Hunter P, et al. (2008) Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 58: 875-887.
24. Gullick NJ, Evans HG, Church LD, Jayaraj DM, Filer A, et al. (2010) Linking power Doppler ultrasound to the presence of Th17 cells in the rheumatoid arthritis joint. PLoS One 5 (9).: pii: e12516.
25. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, et al. (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 63: 73-83.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
27. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
28. Balsa A, Carmona L, González-Alvaro I, Belmonte MA, Tena X, et al. (2004) Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 31: 40-46.
29. Shen H, Goodall JC, Hill Gaston JS, (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum 60: 1647-1656.
30. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F, (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8: 942-949.
31. Syversen SW, Goll GL, van der Heijde D, Landewé R, Lie BA, et al. (2010) Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study. Ann Rheum Dis 69: 345-351.
32. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, et al. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 12: 255-263.
33. Fox DA, (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives. Arthritis Rheum 40: 598-609.
34. Davis LS, Cush JJ, Schulze-Koops H, Lipsky PE, (2001) Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells. Arthritis Res 3: 54-64.
35. Konttinen YT, Pettersson T, Kemppinen P, Friman C, (1990) Spontaneous and in vitro activation of synovial fluid and peripheral blood lymphocytes in rheumatoid arthritis. Clin Rheumatol 9: 325-332.
36. Daha NA, Toes RE, (2011) Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol 7: 202-203.
37. Firestein GS, (2005) Pathogenesis of rheumatoid arthritis: how early is early? Arthritis Res Ther 7: 157-159.
38. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, et al. (2008) Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med 205: 2491-2497.
39. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, et al. (2011) One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis. [abstract]. Arthritis Rheum 63 Suppl 10: 401.
40. Genovese MC, Greenwald MW, Cho CS, Berman A, Jin L, et al. (2011) A Phase 2 Study of Multiple Subcutaneous Doses of LY2439821, An Anti-IL-17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis in Two Populations: Naïve to Biologic Therapy or Inadequate Responders to Tumor Necrosis Factor Alpha Inhibitors. [abstract]. Arthritis Rheum 63 Suppl 10: 2591.